Metastatic Renal Cell Carcinoma ( mRCC)
Also known as: Metastatic Renal Cell Carcinoma / Metastatic Renal Cell Carcinoma (mRCC) / Renal Cell Carcinoma, Metastatic / Renal Cell Carcinoma Metastatic / Renal Cell Cancer Metastatic / Metastatic Renal Cell Cancer / Metastatic renal cell carcinoma (morphologic abnormality) / Metastatic renal cell carcinoma (disorder)
| Drug | Drug Name | Drug Description |
|---|---|---|
| DB00041 | Aldesleukin | A recombinant analog of interleukin-2 used to induce an adaptive immune response in the treatment of renal cell carcinoma. |
| DB00112 | Bevacizumab | A monoclonal anti-vascular endothelial growth factor antibody used in combination with antineoplastic agents for the treatment of many types of cancer. |
| DB00603 | Medroxyprogesterone acetate | A progestin used as a contraceptive and in the treatment of secondary amenorrhea, abnormal uterine bleeding, pain from endometriosis, endometrial and renal carcinomas, paraphilia in males, and GnRH-dependent precocious puberty. |
| DB09035 | Nivolumab | A PD-1 blocking antibody used to treat melanoma, non small-cell lung cancer, renal cell cancer, head and neck cancer, and Hodgkin lymphoma. |
| DB09037 | Pembrolizumab | A PD-1 blocking antibody used to treat various types of cancer, including metastatic melanoma, non small-cell lung cancer, cervical cancer, head and neck cancer, and Hodgkin's lymphoma. |